Back to Dashboard
MYGN · Healthcare

Myriad Genetics Inc

USA Healthcare Filing: 2026-06-30
21/100
Smart-money confidence
Bottom band — money moving out

No standout activity across the feeds we track.

Stocks scoring 0–25 beat the S&P 500 39.9% of the time over the next three months, since 2015. How we measured this →

6
hedge funds
hold it · 2 added, 1 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Market cap
$524M
Industry
Diagnostics & Research
Sector
Healthcare
Exchange
NasdaqGS
About MYRIAD GENETICS INC

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous…

Who's behind the signal
Every informed buyer we can see on MYGN, across all three feeds.
Hedge funds · 6
Citadel Advisors Increased +238%
AQR Capital Management Increased +45%
D.E. Shaw & Co Unchanged
Point72 (Steve Cohen) Decreased −75%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar. MYRIAD GENETICS INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
2
Increasing
1
Decreasing
3
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to reset Pinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Portfolio Allocation
How much of each investor's portfolio is allocated to MYRIAD GENETICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell MYRIAD GENETICS INC or any security.

Get the Weekly Update

Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime · Privacy